INNOVIVE Pharmaceuticals Presents Preliminary Data at ASH Showing INNO-305 Elicits...

INNOVIVE Pharmaceuticals Presents Preliminary Data at ASH Showing INNO-305 Elicits Immune Response in Patients with Myeloid and Thoracic Neoplasms

ATLANTA--(Business Wire)--INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today presented
results from a pilot study examining INNO-305, a Wilms Tumor Protein
(WT1) heteroclitic peptide immunotherapeutic vaccine, in patients with
myeloid and thoracic neoplasms. Preliminary data from the pilot study
suggests repeat administration with INNO-305 is well tolerated and
immune response can be elicited following three vaccinations. The data
were presented at the 49th American Society of Hematology (ASH) Annual
Meeting in Atlanta.

-0-
*T
Date: Saturday, December 8, 2007 from 5:30 pm to 7:30 pm ET

Session Type: Poster Presentation Hall B4, Board #57-I

Abstract: # 903

Title: "Pilot Study of a Wilms Tumor Protein (WT1) Heteroclitic
Peptide Vaccine in Patients with Myeloid and Thoracic
Neoplasms."
*T

WT1 peptide cancer immunotherapeutics target the WT1 transcription
factor, which is over-expressed in hematologic cancers. INNO-305,
composed of four WT-1 peptides, is unique due to its ability to
stimulate both CD8 and CD4 T-cells, which may result in a more robust
and ubiquitous immune response. In the study conducted at the Memorial
Sloan-Kettering Cancer Center, patients receive six vaccinations over
12 weeks with INNO-305 along with the immune adjuvant Montanide.
Preliminary data indicates that a CD4 response was seen in five of six
patients and a CD8 response was seen in patients with HLA-A0201.

"Sloan-Kettering Cancer Center's pilot study of INNO-305 provides
important preliminary data that supports ongoing development of
INN0-305," stated Steve Kelly, President and CEO of INNOVIVE
Pharmaceuticals. "We believe INNO-305 has the potential to elicit
robust immune responses in patients with several serious cancer types
including AML, CML, myelodysplastic syndrome, non small cell lung
cancer and mesothelioma."

About INNO-305

INNO-305, also known as WT1 heteroclitic peptide immunotherapy, is
in a Phase I clinical trial for the treatment of patients with acute
myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and
myelodysplastic syndrome (MDS) as well as patients with non-small cell
lung cancer (NSCLC) and mesothelioma. INNO-305 is unique among WT1
peptide cancer immunotherapeutics because of its ability to stimulate
both CD8 and CD4 T-cells. It is believed that stimulating both types
of T-cells may result in a more robust and ubiquitous immune response.

About INNOVIVE Pharmaceuticals

INNOVIVE Pharmaceuticals, Inc. acquires, develops and
commercializes novel therapeutics addressing significant unmet medical
needs in the fields of oncology and hematology. The company has four
drug programs in clinical development: INNO-406, Tamibarotene,
INNO-206, and INNO-305, for the treatment of chronic myelogenous
leukemia, acute promyelocytic leukemia, small cell lung cancer, and
acute myelogenous leukemia, respectively. For additional information
please visit www.innovivepharma.com.

Forward-looking Statements

This material contains forward-looking statements as defined by
the Private Securities Litigation Reform Act of 1995. These include
statements concerning plans, objectives, goals, strategies, future
events or performance and all other statements which are other than
statements of historical fact, including without limitation,
statements containing words such as "believes," "anticipates,"
"expects," "estimates," "projects," "will," "may," "might" and words
of a similar nature. Such statements involve risks and uncertainties
that could cause actual results to differ materially from those
projected. All forward looking statements assume the Company is able
to immediately obtain additional working capital; without such
additional working capital, the Company will not be able to sustain
its operations or conduct its business. Among other things, there can
be no assurances that any of INNOVIVE's development efforts relating
to its product candidates will be successful. Other risks that may
affect forward-looking information contained in this press release
include INNOVIVE's immediate need for operating capital, the risk that
the results of clinical trials may not support INNOVIVE's claims, the
possibility of being unable to obtain regulatory approval of
INNOVIVE's product candidates, INNOVIVE's reliance on third party
researchers to develop its product candidates and its lack of
experience in developing pharmaceutical products. These and other
risks are discussed in INNOVIVE'S periodic reports filed with the SEC.
The forward-looking statements contained herein represent the judgment
of INNOVIVE as of the date this material was drafted. INNOVIVE
disclaims, however, any intent or obligation to update any
forward-looking statements.

INNOVIVE Pharmaceuticals
Steve Kelly, 212-716-1820
President and CEO
or
Porter Novelli Life Sciences
Rachel Lipsitz, 619-849-5378
Media & Investor Relations

Copyright Business Wire 2007